HighTower Advisors LLC Buys 25,492 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

HighTower Advisors LLC boosted its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 41.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 87,471 shares of the biotechnology company’s stock after purchasing an additional 25,492 shares during the quarter. HighTower Advisors LLC’s holdings in ADMA Biologics were worth $1,748,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Healthcare of Ontario Pension Plan Trust Fund grew its stake in shares of ADMA Biologics by 13.9% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company’s stock valued at $13,171,000 after buying an additional 80,400 shares during the period. Assenagon Asset Management S.A. raised its position in shares of ADMA Biologics by 2.7% during the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock worth $69,454,000 after purchasing an additional 92,281 shares during the period. Citigroup Inc. lifted its holdings in shares of ADMA Biologics by 251.7% in the 3rd quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company’s stock worth $7,741,000 after purchasing an additional 277,138 shares in the last quarter. Seven Eight Capital LP acquired a new stake in ADMA Biologics in the 2nd quarter valued at $1,992,000. Finally, Principal Financial Group Inc. increased its stake in ADMA Biologics by 785.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock valued at $23,872,000 after purchasing an additional 1,059,394 shares in the last quarter. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Trading Down 0.4 %

Shares of ADMA stock opened at $18.59 on Friday. ADMA Biologics, Inc. has a 52-week low of $3.95 and a 52-week high of $23.64. The company has a 50-day simple moving average of $19.02 and a two-hundred day simple moving average of $16.05. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The company has a market capitalization of $4.39 billion, a price-to-earnings ratio of 66.39 and a beta of 0.70.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. The company had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period last year, the business posted $0.01 earnings per share. Research analysts anticipate that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Insider Activity

In other news, CFO Brad L. Tade sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the sale, the chief financial officer now owns 199,433 shares in the company, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 3.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Raymond James raised their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday, November 8th. HC Wainwright boosted their price objective on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 price objective on shares of ADMA Biologics in a research note on Friday, September 20th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.